FDA Finds More Action Required in Less Developed Nations – and Denver
This article was originally published in The Gold Sheet
Executive Summary
FDA inspection data shows a clear trend over the past four years: Investigators are somewhat more likely to find GMP issues at manufacturing facilities in less developed nations and less developed regions. However, the data shows more pronounced variation among FDA districts in the U.S., with some finding far greater needs for corrective action than others.
You may also be interested in...
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.
US FDA Seeks More Power To Confront ‘Shadow’ Factory Challenges
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find manufacturer of contaminated eye drops that disappeared.